

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC and AMNEAL
PHARMACEUTICALS OF NEW YORK, LLC,
Petitioners,

v.

ALMIRALL, LLC
Patent Owner

Case IPR2019-00207

U.S. Patent No. 9,517,219

**DECLARATION OF BOZENA B. MICHNIAK-KOHN, Ph.D., FAAPS,
M.R.Pharm.S.**

TABLE OF CONTENTS

I.	Overview.....	3
II.	My background and qualifications	4
III.	Basis for my opinion.....	7
IV.	Person of ordinary skill in the art	9
V.	State of the art before November 20, 2012	11
VI.	The '219 patent and its claims.....	19
	A. Independent claims 1 and 6.....	20
	B. Dependent claims 2-8.....	21
VII.	Claims 1-4 and 6-7 would have been obvious over Garrett in view of Nadau-Fourcade.....	22
	A. Garrett (AMN1004).....	23
	B. Nadau-Fourcade (AMN1005)	25
	C. Independent claims 1 and 6.....	25
	1. A POSA would have had reason to prepare a topical composition comprising “about 7.5% w/w dapsone,” “about 30% w/w to about 40% w/w diethylene glycol monoethyl ether,” and “water,” wherein “the composition does not comprise adapalene”	31
	2. A POSA would have had a reason to prepare a topical composition comprising “about 2% w/w to about 6% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer”	34
	3. A POSA would have had reason to prepare a topical composition comprising “about 30% w/w diethylene glycol monoethyl ether” and “about 4% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer”	37
	4. The claimed compositional components are well-known for use in topical compositions and therefore a POSA would have had a reasonable expectation of successfully combining them.....	39
	D. Dependent Claims 2-4 and 7	41

Inter Partes Review of U.S. Patent No. 9,517,219
Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
(Exhibit 1002)

1.	Claim 2	41
2.	Claim 3	42
3.	Claims 4 and 7.....	42
VIII.	Claims 1-4 and 6-7 would have been obvious over Garrett in view of Bonacucina	43
A.	Bonacucina (AMN1015).....	43
B.	Independent claims 1 and 5	45
1.	A POSA would have had reason to prepare a topical composition comprising “about 7.5% w/w dapsone,” “about 30% w/w to about 40% w/w diethylene glycol monoethyl ether,” and “water,” wherein “the composition does not comprise adapalene”	49
2.	A POSA would have had reason to prepare a topical composition comprising “about 2% w/w to about 6% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer”	53
3.	A POSA would have had reason to prepare a topical composition comprising “about 30% w/w diethylene glycol monoethyl ether” and “about 4% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer”	60
4.	The claimed compositional components are well-known for use in topical compositions and therefore a POSA would have had a reasonable expectation of successfully combining them.....	62
C.	Dependent Claims 2-4 and 7	64
1.	Claim 2	64
2.	Claim 3	65
3.	Claims 4 and 7.....	65
IX.	No objective indicia of non-obviousness exist.....	66
A.	Incompatibility and smaller particle size would not have been unexpected.	66
B.	There was no “teaching away” from combining the claimed components in the prior art.....	72
X.	Conclusion	72

*Inter Partes Review of U.S. Patent No. 9,517,219
Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
(Exhibit 1002)*

I, Bozena B. Michniak-Kohn, do hereby declare as follows:

I. Overview

1. I am over the age of 18 and otherwise competent to make this declaration. I have been retained as an expert on behalf of Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (“Amneal”). I understand from counsel this declaration is being submitted together with a petition for *Inter Partes* Review (“IPR”) of claims 1-8 of U.S. Patent No. 9,517,219 (“the ’219 patent”) (AMN1001).

2. I am being compensated for my time in connection with this IPR at my standard legal consultant rate of \$650/hr. I have no personal or financial interest in Amneal or in the outcome of this proceeding.

3. In preparing this declaration, I have reviewed the ’219 patent (AMN1001) and considered each of the documents cited therein, in light of the general knowledge in the art before November 20, 2012. I have also relied upon my experience in the relevant art and considered the viewpoint of a person of ordinary skill in the art (“POSA”; defined in § IV) before November 20, 2012.

4. As set forth below, claims 1-4 and 6-7 of the ’219 patent would have been obvious over the prior art. I understand from counsel that another expert on behalf of Amneal will address claims 5 and 8. Each of the claimed compositional components were known in the art for use in topical compositions. Specifically,

*Inter Partes Review of U.S. Patent No. 9,517,219
Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
(Exhibit 1002)*

each of the elements were known for use in dapstone compositions, many in the same amounts as claimed. Each element is performing the same function it is known for in the art, and the prior art teaches that modifications to these amounts were within the skill of the art and would result in predictable changes to the compositions.

5. This declaration sets forth my opinion that a POSA would have had a reason to arrive at the subject matter recited in claims 1-4 and 6-7 of the '219 patent, with a reasonable expectation of success, by combining either:

(1) the disclosures of Garrett (AMN1004), Nadau-Fourcade (AMN1005), and a POSA's knowledge of the prior state of the art, or

(2) the disclosures of Garrett (AMN1004), Bonacucina (AMN1015), and a POSA's knowledge of the prior state of the art, as discussed in this declaration below.

II. My background and qualifications

6. My qualifications and credentials are fully set forth in my *curriculum vitae*, attached as AMN1003. I am an expert in the field of topical pharmaceutical compositions and transdermal drug delivery systems. Over the past 37 years, I have accumulated significant experience designing and testing novel formulations for topical and transdermal drug delivery systems including creams, gels, emulsions, and micro- and nano-carrier systems.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.